Year: 2022

Cellectis’ Pipeline Overview Cellectis’ Fully Owned & Licensed Product Candidate PipelineUCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a durable minimal residual disease (MRD)-negative complete response that continues beyond 12 months BALLI-01 study (evaluating UCART22) now enrolling patients with product candidate manufactured in-house at DL2 AMELI-01 study (evaluating UCART123) now enrolling patients in a two-dose regimen arm at DL2NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...

Cellectis’ Pipeline Overview Cellectis’ Fully Owned & Licensed Product Candidate PipelineUCART22: anti-tumor activity observed in 60% (n=3) of patients at DL3 using FCA lymphodepletion UCART123: 25% (n=2) of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a durable minimal residual disease (MRD)-negative complete response that continues beyond 12 months BALLI-01 study (evaluating UCART22) now enrolling patients with product candidate manufactured in-house at DL2 AMELI-01 study (evaluating UCART123) now enrolling patients in a two-dose regimen arm at DL2NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) — Cellectis S.A. (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...

Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohortsOverall degree of improvement was greater in bilateral compared to unilateral cohortsAAV2-hAQP1 appears safe and well tolerated at each dose testedWebcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ETLONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoing Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 radiation-induced xerostomia (RIX). “We are very encouraged by the...

Derek Kerr to Step Down From CFO Role at End of Year Following Long-Planned Succession Process; Kerr to Remain at American as Vice Chair, President of American Eagle and Strategic AdvisorAmerican Airlines Names Devon May Chief Financial Officer American Airlines Names Devon May Chief Financial OfficerFORT WORTH, Texas, Dec. 13, 2022 (GLOBE NEWSWIRE) — American Airlines Group Inc. (NASDAQ: AAL) today announced that Devon May has been named Chief Financial Officer following a long-planned succession process. May, who is currently the airline’s senior vice president of Finance and Investor Relations, will assume the CFO role effective Jan. 1, 2023. He will report to American’s CEO Robert Isom. American’s current CFO Derek Kerr will remain at the airline as Vice Chair, President of American Eagle and Strategic Advisor. He will...

DALLAS, Dec. 13, 2022 (GLOBE NEWSWIRE) — Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic” or the “Company”), a growth-oriented aerosol manufacturing company focused on natural relief innovations through trusted aerosol delivery, announces today that it has moved three (3) proprietary pharmaceutical grade patents from provisional to non-provisional status. Donal R. Schmidt, Jr. CEO states: “All three patent applications are specially designed for inhalation of CBD and CBG with the expectation they will eventually be approved by the FDA for delivery in a pressurized metered dose inhaler (pMDI).” RTSL previously marketed both CBD and CBG delivered in MDI through pharmacies and physicians before removing them from the public market to focus on research and FDA approval of its inhaled...

— Patents support Gritstone’s pioneering work in the application of next-generation samRNA vaccine technology in oncology and infectious disease — EMERYVILLE, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that the United States Patent and Trademark Office (USPTO) recently issued two new patents related to the company’s novel self-amplifying mRNA (samRNA) vaccine platform technology. U.S. Patent No. 11,504,421 includes claims covering Gritstone’s individualized cancer vaccine candidates (GRANITE). U.S. Patent No. 11,510,973 includes claims covering antigen-encoding samRNA vectors and has broad applicability across Gritstone’s candidates in oncology and infectious disease. “Self-amplifying...

Toronto Stock Exchange: TF TORONTO, Dec. 13, 2022 (GLOBE NEWSWIRE) — Timbercreek Financial Corp. (TSX: TF) (the “Company” or “Timbercreek Financial”) today provided commentary and clarification on its loans to Groupe Sélection Inc. (“Groupe Sélection”), one of Canada’s largest private companies in the retirement community sector. On November 13, 2022, Groupe Sélection filed an application under the Companies’ Creditors Arrangement Act (CCAA) in order to proceed with a restructuring. Several recent media articles have stated that Timbercreek’s investments to Groupe Sélection total approximately $212 million. Timbercreek is in the business of originating commercial mortgages and often works with third-party lenders to share loans based on different risk and return criteria. This total amount represents the gross amount of the first...

Fluence-made battery packs, to be developed in the U.S., will allow greater global supply chain flexibility to best serve customers with rapid energy storage deployment ARLINGTON, Va., Dec. 13, 2022 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (“Fluence”) (NASDAQ: FLNC), a leading global provider of energy storage products, services, and cloud-based software for renewables and storage, today announced a strategic plan to develop Fluence-made battery packs, with production set to begin in early 2024 in the United States. The move is intended to give Fluence greater control over the global supply chain and increase standardization across products. Moreover, we believe that this plan to develop and introduce Fluence-made battery packs will assist Fluence customers in accessing incentives under the Inflation Reduction Act of 2022. The Fluence-designed...

Executive Management and Board Member Appointments to Take Effect January 1, 2023 CHICAGO and VANCOUVER, British Columbia, Dec. 13, 2022 (GLOBE NEWSWIRE) — Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of RISE Dispensaries, today announced the appointments of four executive leadership positions and one new board member. The leadership promotions include Anthony Georgiadis to President, Matt Faulkner to Chief Financial Officer, and Bret Kravitz to General Counsel and Secretary, as well as the appointments of Rachel Albert to Chief Administrative Officer and Dawn Wilson Barnes to the Company’s board of directors. These appointments will be effective January 1, 2023. “These changes reflect the natural evolution of high-performing team members...

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the Company has entered into a Common Stock Purchase Agreement (the “Agreement”) for up to $25 million with Lincoln Park Capital Fund (“LPC”), a Chicago-based institutional investor and long-term Marker shareholder. Under the terms of the Agreement, LPC has committed to purchase up to $25 million of shares of the Company’s common stock at Marker’s sole discretion from time to time during a 24-month period upon satisfaction of the conditions in the Agreement, including after a registration statement...